Cogent Biosciences, Inc.(COGT)

Biotechnology · Waltham, MA

$30.87-0.15 (-0.48%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T11:41:49.076Z.

Stored calculation inputs

Calculation as of: 2026-10-06T11:41:49.076Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,274,695,160
Total debt · period ending 2026-06-30: 244,261,000
Cash · period ending 2026-06-30: 181,172,000
TTM free cash flow · period ending 2026-06-30: -309,240,000

FMP input reference: 8c517f571e23d8c9640577b72a0d01a1674ca2fb527f0620093024032568825b

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

COGT EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

COGT Competitors' EV/FCF Ratio

COGT

Cogent Biosciences, Inc.

Current

Market Cap

$5.27B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DOCS

Doximity, Inc.

vs COGT

Market Cap

$5.35B

EV/FCF Ratio

16.98x

TTM Avg

20.97x

3Y Avg

34.66x

5Y Avg

46.39x

MMSI

Merit Medical Systems, Inc.

vs COGT

Market Cap

$5.20B

EV/FCF Ratio

27.39x

TTM Avg

27.85x

3Y Avg

42.08x

5Y Avg

46.24x

SRRK

Scholar Rock Holding Corporation

vs COGT

Market Cap

$5.20B

EV/FCF Ratio

N/A

TTM Avg

29.52x

3Y Avg

29.52x

5Y Avg

29.52x

ERAS

Erasca, Inc.

vs COGT

Market Cap

$5.11B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRSP

CRISPR Therapeutics AG

vs COGT

Market Cap

$5.53B

EV/FCF Ratio

N/A

TTM Avg

11.36x

3Y Avg

56.18x

5Y Avg

56.18x

BLLN

BillionToOne, Inc.

vs COGT

Market Cap

$5.02B

EV/FCF Ratio

139.01x

TTM Avg

178.16x

3Y Avg

178.16x

5Y Avg

178.16x

DNTH

Dianthus Therapeutics, Inc.

vs COGT

Market Cap

$4.92B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DFTX

Definium Therapeutics, Inc.

vs COGT

Market Cap

$4.81B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADPT

Adaptive Biotechnologies Corporation

vs COGT

Market Cap

$4.78B

EV/FCF Ratio

N/A

TTM Avg

17.76x

3Y Avg

17.76x

5Y Avg

17.76x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Cogent Biosciences, Inc. (COGT)	$5.27B	N/A	N/A	N/A	N/A
Doximity, Inc. (DOCS)vs ›	$5.35B	16.98x	20.97x	34.66x	46.39x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.20B	27.39x	27.85x	42.08x	46.24x
Scholar Rock Holding Corporation (SRRK)vs ›	$5.20B	N/A	29.52x	29.52x	29.52x
Erasca, Inc. (ERAS)vs ›	$5.11B	N/A	N/A	N/A	N/A
CRISPR Therapeutics AG (CRSP)vs ›	$5.53B	N/A	11.36x	56.18x	56.18x
BillionToOne, Inc. (BLLN)vs ›	$5.02B	139.01x	178.16x	178.16x	178.16x
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.92B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.81B	N/A	N/A	N/A	N/A
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.78B	N/A	17.76x	17.76x	17.76x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Waltham, MA

258 employees

www.cogentbio.com

Healthcare / Biotechnology